receptor blocker – Communicable Diseases Research

Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials

심혈관계 약물 및 코로나19 임상 결과: 무작위 대조 시험의 체계적인 검토 및 메타 분석

Review

Published on 2022-08-012022-09-11
Journal: British Journal of Clinical Pharmacology [Category] 임상, 진단,

Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease

안지오텐신 II 수용체 차단제 섭취량은 심혈관 동반 질환 및 CovID-19 질환 환자에서 염증 활성화의 마커 감소 및 사망률 감소와 관련이있다.

Research Article

Published on 2021-10-212022-09-10
Journal: PLoS ONE [Category] MERS, SARS, 바이오마커,

[키워드] 95% CI ACE2 ACE2 expression ACEi Activation aldosterone analyzed angiotensin Angiotensin II angiotensin receptor blocker Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor ARB ARBs baseline cardiovascular comorbidities cardiovascular comorbidity Cell consecutive patient Course COVID-19 COVID-19 disease Critical CRP death decreased mortality disease severity driven by drug early phase enrolled Enzyme inhibitor European human lung hypertension IL-6 incidence Inflammatory Inflammatory marker inflammatory markers Kaplan-Meier analysis less leukocyte leukocytes marker Mortality neutrophil Neutrophils not altered open Patient patients patients with COVID-19 procalcitonin RAAS receptor receptor blocker reduced Renin risk SARS-CoV-2 SARS-CoV2 significantly significantly increased significantly lower survey systemic inflammatory These data threshold virus
[DOI] 10.1371/journal.pone.0258684 PMC 바로가기 [Article Type] Research Article

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

인간 PSC 유래 심근세포 및 1차 내피 세포에서 항고혈압 약물 치료 및 SARS-CoV-2 감염에 대한 감수성

Article

Published on 2021-10-122022-09-11
Journal: Stem Cell Reports [Category] SARS, 유전자 메커니즘,

[키워드] ACE2 ACEi acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alter angiotensin angiotensin receptor blocker angiotensin-converting enzyme 2 angiotensin-converting enzyme inhibitor Antihypertensive drug antihypertensive medication ARB Cell cell type Coronavirus-2 COVID-19 drug treatment endothelial Endothelial cell endothelial cells Enzyme inhibitor heart hPSC-derived cardiomyocytes Immunity interferon involved Lisinopril losartan MAPK medications membrane-bound mitogen mitogen-activated protein kinase modulate multicenter trials Necrosis NF-κB not affect nuclear pathogenicity Pathways Protein protein coding gene protein coding genes protein kinase receptor receptor blocker RNA RNA sequencing SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 signaling pathways significant difference significant differences stem cells susceptibility therapy TNF toxic effect toxic effects Transcriptome transcriptome change transcriptome changes Treatment Tumor tumor necrosis tumor necrosis factor
[DOI] 10.1016/j.stemcr.2021.08.018 PMC 바로가기 [Article Type] Article

Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

COVID-19 호흡기 질환에 대한 안지오텐신 수용체 차단제의 통제된 평가를 위한 프로토콜(CLARITY): 무작위 통제 시험

Study Protocol

Published on 2021-08-282022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 7-point ordinal scale accumulating ACE2 activities activity adaptive angiotensin Angiotensin II angiotensin receptor blocker Angiotensin receptor blockers angiotensin-converting enzyme 2 ARB ARBs AT1R Bayesian adaptive design bind blinded blocked CLARITY clinical commenced Controlled Controlled trial COVID-19 COVID-19 severity daily dose death determine disease downregulation Effect Effectiveness enzyme High-risk patients include India interim analysis membrane membrane-bound Mortality offer Open-label Ordinal Scale outcome Placebo Pragmatic Predictive primary endpoint pro-fibrotic pro-inflammatory Probability randomised controlled trial RAS RCT receptor receptor blocker Receptor Blockers recruitment reduce reducing registry Renin renin-angiotensin system respiratory respiratory outcomes responsible Safe Sample size SARS-CoV-2 secondary Secondary outcomes Standard of care supplementary material supply Treatment treatment allocation Trial Trial registration Two-arm
[DOI] 10.1186/s13063-021-05521-0 PMC 바로가기 [Article Type] Study Protocol

Safety and Efficacy of Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19 Population

COVID-19 인구에서 레닌-안지오텐신-알도스테론계 억제제의 안전성 및 효능

Meta-Analysis

Published on 2021-07-012022-09-11
Journal: High blood pressure & cardiovascular prevention : [Category] SARS, 임상,

[키워드] 95% CI ACEi age aldosterone Analysis angiotensin angiotensin receptor blocker angiotensin-converting enzyme inhibitor antibodies ARB association clearance clinical manifestation clinical manifestations Comorbidities contraindication converting enzyme inhibitor COVID-19 COVID-19 patient database Digital enzyme Enzyme inhibitor group higher odd higher odds ICU admission inhibitor inhibitors intensive care units males Mortality negative RT-PCR observational studies observational study Odds ratio outcome outcomes pandemic Population Primary outcome progression RAASi receptor receptor blocker Renin renin-angiotensin-aldosterone system Renin–angiotensin–aldosterone system inhibitors. RT-PCR Safety secondary outcome Seropositivity Sex Symptoms System viral clearance was used worsening
[DOI] 10.1007/s40292-021-00462-w PMC 바로가기 [Article Type] Meta-Analysis

What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak

토실리주맙은 어떻습니까? COVID-19 발생 기간 동안 NYC 병원의 후향적 연구

Randomized Controlled Trial

Published on 2021-04-082022-08-13
Journal: PLoS ONE [Category] MERS, SARS, 임상, 진단,

[키워드] 7-point ordinal scale 95% CI absence Admission Bacterial infection Bacterial infections bacterial superinfection bacterial superinfections baseline Control Corticosteroid Corticosteroids COVID-19 COVID-19 outbreak demographics Endpoint evaluated Evidence evidence of gastrointestinal perforation Health hospital Hypoxemia Illness severity incidence include increase in independent independent of inflammatory phase interleukin-6 interleukin-6 receptor large academic medical center measure Methylprednisolone New York City no evidence of no increase Ordinal Scale outcome Oxygenation Patient patients with COVID-19 primary endpoint primary endpoints Primary outcomes receiving receptor blocker Result Retrospective analysis Retrospective study secondary secondary bacterial infection Secondary bacterial infections Secondary endpoints severe disease Support t-test Tocilizumab ventilator ventilator free survival ventilator-free survival
[DOI] 10.1371/journal.pone.0249349 PMC 바로가기 [Article Type] Randomized Controlled Trial

Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential

항고혈압 및 항-COVID-19 잠재성을 지닌 높은 용해도 및 내구성을 갖는 공동-비정질 발사르탄/니코틴아미드 조성물의 형성에서 수소 결합의 역할

Article

Published on 2021-04-012022-08-31
Journal: Molecular Pharmaceutics [Category] 치료제,

[키워드] (nicotinamide) acting active pharmaceutical ingredient analyses angiotensin Angiotensin II anti-hypertensive applied approaches Bioavailability bond caused characterized co-amorphization conformational change conformational changes coronavirus COVID-19 Density functional theory Donor drug drugs Effects Efficacy exhibit flexible Formation functional heterodimeric hydrogen Hydrogen bond hydrogen bonds hypertension ingredient Interaction key factor liquid low molecular weight lung market molecules NIC nicotinamide pandemic coronavirus Physicochemical properties Potential quantum theory receptor receptor blocker responsible role SARS-COV-2 infection solid dispersion solubility treat valsartan X-ray
[DOI] 10.1021/acs.molpharmaceut.0c01096 PMC 바로가기 [Article Type] Article

Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension

COVID-19 환자를 대상으로 한 레닌-안지오텐신계 억제제의 무작위 시험에 대한 전향적 메타분석 프로토콜: 국제고혈압 학회(International Society of Hypertension)의 주도

Article

Published on 2021-02-162022-08-31
Journal: BMJ Open [Category] meta-analysis, 임상,

[키워드] ACE inhibitor ACE inhibitors ACEi ACEi/ARB Admission all-cause mortality Analysis Angiotensin II approval ARB ARBs Cardiology cardiovascular event Cardiovascular events clinical decision Comorbidities contribute Controlled controlled trials country COVID-19 Decision making drug Efficacy eligible Ethics Ethnicity Follow-up followed by Formal Guidance Health policy hypertension identify include inclusion criteria infected with SARS-CoV-2 Informed consent inhibitor initiated intensive care mechanical ventilation Meta-analysis occur outcome Patient patients with COVID-19 peer-reviewed performed Primary outcome Prospective protocol public health randomised randomised controlled trial Randomised controlled trials Randomised trial RCT RCTs receptor receptor blocker recruitment renin-angiotensin system responsibility secondary Secondary outcomes smoking smoking status Society study duration therapy Trial widespread
[DOI] 10.1136/bmjopen-2020-043625 PMC 바로가기 [Article Type] Article

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

칸데사르탄과 캡토프릴을 사용한 실험 데이터는 COVID-19에서 양날의 검 효과가 없음을 나타냅니다

Article

Published on 2021-02-122022-09-11
Journal: Clinical Science (London, England : 1979) [Category] 유전자 메커니즘,

[키워드] ACE ACE2 ACE2 expression ACEi ACEIs ADAM17 angiotensin angiotensin-converting enzyme 2 Anti-inflammatory anti-inflammatory response antihypertensives. ARB ARBs AT1 AT2 blood pressure candesartan Captopril Cell cells change COVID-19 Culture culture medium cultures Cytokines decrease drug drugs entry receptor expression full-length healthy hyperglycemia increase increase in inhibited lung mechanisms medium metabolic syndrome obesity Patient pneumocyte Proinflammatory cytokine proinflammatory cytokines promote RAS RAS activity RATs receptor receptor blocker receptors regulate Renin renin-angiotensin system severe COVID-19 soluble ACE2 spike Spike protein syndrome tissue transmembrane up-regulated up-regulation Viral viral entry viral spike protein virus
[DOI] 10.1042/CS20201511 PMC 바로가기 [Article Type] Article

The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities

신종 코로나바이러스 폐렴 및 기저 동반 질환의 치료에서 ACE2의 양방향 전환 역할

Review

Published on 2020-12-312022-09-10
Journal: Molecules [Category] MERS, SARS, 치료제,

[키워드] ACE ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 addition analyzed angiotensin angiotensin receptor blocker angiotensin-converting enzyme II (ACE2) anti-SARS-CoV-2 caused Comorbidities coronavirus disease Coronavirus disease 2019 Coronavirus pneumonia Coronavirus-2 COVID-19 described domain drug Drug discovery enzyme II epithelial cells functional globe higher affinity host cells hot spot hypertension Infection information inhibitor interact Intervention lung failure Lung injury membrane-bound Mortality Novel coronavirus novel coronavirus pneumonia Patient pharmacological Pneumonia potential treatment option Protein pulmonary epithelial cells RAS receptor receptor blocker recombinant ACE2 Renin renin-angiotensin system renin-angiotensin system (RAS) respiratory role SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 spike protein Severe acute respiratory syndrome Severe acute respiratory syndrome (SARS) severe acute respiratory syndrome Coronavirus Spike protein Spread suggested switch the SARS-CoV-2 therapeutic strategy Treatment Viral
[DOI] 10.3390/molecules26010142 PMC 바로가기 [Article Type] Review